These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 26087799)

  • 1. Treatment of multicentric Castleman’s disease in HIV-1 infected and uninfected patients: a systematic review.
    Rokx C; Rijnders BJ; van Laar JA
    Neth J Med; 2015 Jun; 73(5):202-10. PubMed ID: 26087799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An HHV-8 Positive HIV Negative Multicentric Castleman's Disease, who Responded well to Rituximab Alone.
    Kounatidis D; Rontogianni D; Sampaziotis D; Vardaka M; Giatra C; Dolapsakis C; Margellou E; Vallianou NG
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(1):84-86. PubMed ID: 30827270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.
    Nicoli P; Familiari U; Bosa M; Allice T; Mete F; Morotti A; Cilloni D; Saglio G; Guerrasio A
    Int J Hematol; 2009 Oct; 90(3):392-396. PubMed ID: 19756920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-associated multicentric Castleman disease.
    Oksenhendler E
    Curr Opin HIV AIDS; 2009 Jan; 4(1):16-21. PubMed ID: 19343828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The successful treatment of haemophagocytic syndrome in patients with human immunodeficiency virus-associated multi-centric Castleman's disease.
    Stebbing J; Ngan S; Ibrahim H; Charles P; Nelson M; Kelleher P; Naresh KN; Bower M
    Clin Exp Immunol; 2008 Dec; 154(3):399-405. PubMed ID: 19222502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease.
    Hoffmann C; Schmid H; Müller M; Teutsch C; van Lunzen J; Esser S; Wolf T; Wyen C; Sabranski M; Horst HA; Reuter S; Vogel M; Jäger H; Bogner J; Arasteh K
    Blood; 2011 Sep; 118(13):3499-503. PubMed ID: 21778341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.
    Uldrick TS; Polizzotto MN; Aleman K; Wyvill KM; Marshall V; Whitby D; Wang V; Pittaluga S; O'Mahony D; Steinberg SM; Little RF; Yarchoan R
    Blood; 2014 Dec; 124(24):3544-52. PubMed ID: 25331113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease.
    Gérard L; Michot JM; Burcheri S; Fieschi C; Longuet P; Delcey V; Meignin V; Agbalika F; Chevret S; Oksenhendler E; Galicier L
    Blood; 2012 Mar; 119(10):2228-33. PubMed ID: 22223822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases.
    Nagao A; Nakazawa S; Hanabusa H
    J Hematol Oncol; 2014 Jan; 7():10. PubMed ID: 24438824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicentric Castleman's disease in HIV infection: a systematic review of the literature.
    Mylona EE; Baraboutis IG; Lekakis LJ; Georgiou O; Papastamopoulos V; Skoutelis A
    AIDS Rev; 2008; 10(1):25-35. PubMed ID: 18385778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brief communication: rituximab in HIV-associated multicentric Castleman disease.
    Bower M; Powles T; Williams S; Davis TN; Atkins M; Montoto S; Orkin C; Webb A; Fisher M; Nelson M; Gazzard B; Stebbing J; Kelleher P
    Ann Intern Med; 2007 Dec; 147(12):836-9. PubMed ID: 18087054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of aggressive HIV-associated multicentric Castleman's disease: a case report.
    Flejsierowicz M; Ahmed MS; Kotov P; Cheng YC
    WMJ; 2008 Jul; 107(4):191-4. PubMed ID: 18702436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab.
    Ide M; Kawachi Y; Izumi Y; Kasagi K; Ogino T
    Eur J Haematol; 2006 Feb; 76(2):119-23. PubMed ID: 16405432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of iatrogenic multicentric Castleman's disease arising due to recrudescence of HHV-8 in a liver transplant patient.
    Speicher DJ; Sehu MM; Mollee P; Shen L; Johnson NW; Faoagali JL
    Am J Transplant; 2014 May; 14(5):1207-13. PubMed ID: 24674650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome.
    Alzahrani M; Hull MC; Sherlock C; Griswold D; Leger CS; Leitch HA
    Leuk Lymphoma; 2015 May; 56(5):1246-51. PubMed ID: 25093377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fifty years of multicentric Castleman's disease.
    Waterston A; Bower M
    Acta Oncol; 2004; 43(8):698-704. PubMed ID: 15764213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete remission in a pancytopenic HIV negative, HHV-8 positive patient with multicentric Castleman's disease induced with anti-CD20.
    Cervera Grau JM; Galiana Esquerdo G; Llorca Ferrándiz C; Briceño García H; Díaz Castellano M; Férriz Moreno P
    Clin Transl Oncol; 2006 Jul; 8(7):540-1. PubMed ID: 16870545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable remission of both multicentric Castleman's disease and Kaposi's sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patient.
    Murphy C; Hawkes E; Chionh F; Chong G
    J Clin Pharm Ther; 2017 Feb; 42(1):111-114. PubMed ID: 27790727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-associated multicentric Castleman disease.
    Reddy D; Mitsuyasu R
    Curr Opin Oncol; 2011 Sep; 23(5):475-81. PubMed ID: 21760504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease.
    Bower M; Veraitch O; Szydlo R; Charles P; Kelleher P; Gazzard B; Nelson M; Stebbing J
    Blood; 2009 May; 113(19):4521-4. PubMed ID: 19224759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.